Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics

Andrew B. Waight¹, Katja Bargsten², Svetlana Doronina¹, Michel O. Steinmetz², Django Sussman¹*, Andrea E. Prota²*

¹ Department of Protein Sciences, Seattle Genetics, Inc., Bothell, WA, United States of America,
² Department of Biology and Chemistry, Laboratory of Biomolecular Research, Paul Scherrer Institut, Villigen PSI, Switzerland

* Current address: Department of Biochemistry, University of Zurich, Zürich, Switzerland
dsuissman@seagen.com (DS); andrea.prota@psi.ch (AEP)

Abstract

The auristatin class of microtubule destabilizers are highly potent cytotoxic agents against several cancer cell types when delivered as antibody drug conjugates. Here we describe the high resolution structures of tubulin in complex with both monomethyl auristatin E and F and unambiguously define the trans-configuration of both ligands at the Val-Dil amide bond in their tubulin bound state. Moreover, we illustrate how peptidic vinca-site agents carrying terminal carboxylate residues may exploit an observed extended hydrogen bond network with the M-loop Arg278 to greatly improve the affinity of the corresponding analogs and to maintain the M-loop in an incompatible conformation for productive lateral tubulin-tubulin contacts in microtubules. Our results highlight a potential, previously undescribed molecular mechanism by which peptidic vinca-site agents maintain unparalleled potency as microtubule-destabilizing agents.

Introduction

Microtubules are highly dynamic cytoskeletal protein polymers composed of repeating αβ-tubulin heterodimers, and are essential for multiple cellular processes in eukaryotes including cell division, differentiation, transport and motility. Microtubule dynamic instability arises via the regulated association and disassociation events of individual tubulin dimers from microtubule ends and is linked to GTP hydrolysis [1,2]. The non-equilibrium polymerization of microtubules can be abruptly reversed by a disassembly process known as catastrophe, which releases GDP-tubulin [3]. The exchange of GDP to GTP regenerates the polymerizable form of tubulin, and therefore plays an important role in the cellular regulation of microtubule dynamics [4].

The tubulin dimers of the microtubule cytoskeleton are the cellular target for a substantial number of naturally occurring cytotoxic agents that are believed to act primarily by the disruption of mitosis [5], and by interfering with interphase microtubule function, such as trafficking...
that is essential for cell metabolism and/or signaling [6]. These molecules are loosely classified by the general regions on the tubulin dimer to which they bind. The tubulin binding agents which bind at or near to sites of the vinca alkaloids are referred to as vinca-site antimitotics [7]. Vinca-site binding compounds originate from disparate organisms and exhibit a variety of chemical compositions [8]. Several of these compounds, such as vincristine and vinblastine, have been used for more than four decades as clinically effective cancer therapeutics [7]. More recently, highly potent antimitotics such as maytansine and monomethyl auristatin E (MMAE) have been successfully implemented as cytotoxic payloads for antibody-drug conjugates (ADC) [9–11]. These advances have resulted in newly approved cancer therapeutics with outstanding efficacy.

MMAE is a highly potent synthetic analog of the natural peptide product dolastatin 10 [9,12,13]. The mechanisms by which these molecules act on tubulin dimers include the induction of curved aggregates and inhibition of nucleotide exchange [14]. MMAE comprises the four amino acids monomethylvaline (MeVal), valine (Val), dolaisoleuine (Dil) and dolaprine (Dap), and the carboxy-terminal amine norephedrine (Fig 1A). This agent provides the cytotoxic activity for the ADC Brentuximab vedotin, currently designated for relapsed Hodgkin lymphoma and anaplastic large cell lymphoma [11]. Brentuximab vedotin consists of approximately four MMAE molecules conjugated via a protease-cleavable linker to an anti-CD30 antibody. Upon binding to cells expressing the CD30 epitope, the ADC is internalized and MMAE is released into the cytosol resulting in mitotic arrest and apoptosis [9]. The cleaved and released MMAE molecule is indistinguishable from the freely synthesized compound.

Crystal structures of vinca-site ligands in complex with tubulin show that the binding region of these compounds is located at the interface between two longitudinally aligned tubulin dimers, between a β1-tubulin subunit and the adjacent α2-tubulin subunit [15,16]. The positioning of vinca-site compounds in this region suggests that these molecules maintain the two longitudinally aligned tubulin dimers in a curved conformation that is incompatible with the straight structure of microtubules. This model of curvature between dimers is supported in vitro by the formation of curved spiral or ring shaped aggregates that are, for example, induced by the vinca alkaloids vinblastine, cryptophycin and dolastatin [8].

Biophysical and biochemical experiments with free tubulin and dolastatin 10 have suggested that this compound is a non-competitive inhibitor of the vinca alkaloids and shows a much greater inhibition of nucleotide exchange [17]. These observations were the first demonstration that the members of the auristatin class of compounds interact with a structurally distinct region from the vinca site, termed the peptide site [17]. Low resolution crystal structures of dolastatin 10 derivatives in complex with tubulin have further confirmed the region of binding for the auristatins, which overlaps with that of the vinca site but extends significantly further to interact with the bound GDP ligand at the exchangeable site on β-tubulin [18,19]. In addition, recently reported moderate resolution (between 3.1 and 3.5 Å) crystal structures of dolastatin 10 analogs have described the occurrence of a cis-configuration at the Val-Dil amide bond in their bound state to tubulin, which is in contrast to the trans-configuration observed in solution [19]. However, at such low resolutions, the electron density is not detailed enough to unambiguously distinguish between the two possible configurations of the ligand in the binding site.

To enhance our understanding of how auristatins bind to the peptide site and to elucidate the existing chemical structure-activity relationships of auristatin analogs [12], we have determined the crystal structures of both MMAE and monomethyl auristatin F (MMAF) in complex with tubulin (MMA-structures) to 1.8 and 2.5 Å resolution, respectively. Analysis of these structures allows for the unambiguous determination of the trans-configuration at the Val-
Dil amide bond in the bound state. Moreover, comparison of the MMA-structures and other tubulin structures liganded to vinca-site ligands, including a vinblastine complex in the same crystal form as the MMAs, reveals a cross-talk to the M-loop through Arg278, thereby suggesting an additional general mechanism of microtubule destabilization by vinca-site ligands. Understanding the atomic mechanisms responsible for the potency of MMAE and its derivatives will greatly aid in the development of new antimitotic compounds with auristatin-like properties.

Materials and Methods

Fluorescence polarization binding assay
Sheep brain tubulin was obtained from Cytoskeleton (Cytoskeleton Inc Denver, CO) and exact protein concentration was determined using the DC protein assay (Bio-Rad Laboratories, Hercules, CA) 8 point serial dilutions of tubulin were conducted using FP assay buffer (20 mM PIPES pH 6.9, 1 mM EGTA, 1 mM MgCl₂) at 2X assay concentration (highest amount 20 μM and dilutions occurring at 3.3X concentration). Starting with a 1 mM FITC labeled auristatin stock solution in DMSO probe was diluted to 60 nM in FP assay buffer + 0.008% Tween 20. To initiate the assay, 15 μL of 2X tubulin serial dilution was combined with 15 μL 60 nm FITC labeled stock in the wells of a 384 well plate (Corning #3575) for a final concentration of 30 nM fluorophore and 8 tubulin concentration points (10000.00, 3030.30, 918.27, 278.26, 84.32,
25.55, 7.74, and 0.00 nM) performed in triplicate. The plate was covered with aluminum foil and the reaction was allowed to proceed for 1 hour at room temperature with gentle shaking. Fluorescence polarization was measured on an Envision multilabel reader (Perkin Elmer, Waltham, MA) using an installed FITC FP dual mirror (#2100–4070). Measurements of polarization (milli-polarization units) are defined as (mP) = 1000*(S-G)/(S+G)*P where S and P represent the parallel and perpendicular background subtracted fluorescence count rates following polarized excitation, and G (grating) is an instrument dependent factor calculated from pure fluorophore solution. Binding data was analyzed using Graphpad Prism software (GraphPad Software, Inc. La Jolla, CA). Kd values were extrapolated from tubulin concentration EC50 values calculated from a dose-response variable slope model given by the equation 

\[ Y = \text{Bottom} + \left( \frac{\text{Top-Bottom}}{1+10^{(\text{LogEC50-X}/\text{HillSlope})}} \right) \].

**Protein expression and purification**

Bovine brain tubulin was prepared according to ref. 20 [20]. Methods for the production of T2R-TTL complex using the stathmin-like domain of RB3 and chicken TTL expressed in E. coli, have been described in refs. 21, 22 [21,22] and 23 [23].

**Crystallization, data collection, and structure solution**

Crystals of T2R-TTL were generated as described previously in refs. 21 [21] and 22 [22]. Suitable T2R-TTL crystals were exchanged into reservoir solutions containing either 2 mM MMAE, 1 mM MMAF or 1 mM vinblastine and soaked overnight (MMAE) or for 1 hour, respectively. Soaked crystals were flash cooled in liquid nitrogen following a brief stepwise transfer into cryo solutions containing 15% and 20% glycerol, respectively. T2R-TTL MMAE and vinblastine data were collected at beamlines X10SA and X06SA at the Swiss Light Source (Paul Scherrer Institut, Villigen, Switzerland), respectively. T2R-TTL MMAF data were collected at data beamline 4.2.2 at the Advanced Light Source (Lawrence Berkeley Labs, Berkeley, USA). Images were indexed and processed using XDS, and structure solution by the difference Fourier method and refinement were performed using the PHENIX package. Model building was carried out iteratively using the Coot software. Data collection and refinement statistics are given in Table 1. The atomic coordinates have been deposited in the Protein Data Bank, www.rcsb.org [PDB ID code 5IYZ (T2R-TTL-MMAE), 5J2U (T2R-TTL-MMAF), 5J2T (T2R-TTL-vinblastine)].

**Structural analysis and figure preparation**

Molecular graphics and analyses were performed with the UCSF Chimera package and PyMol (The PyMOL Molecular Graphics System, Version 1.5.0.5. Schrödinger, LLC). Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311). Chains in the T2R-TTL complex were defined as follows: chain A, α-tubulin-1; chain B, β-tubulin-1; chain C, α-tubulin-2; chain D, β-tubulin-2; chain E, RB3; and chain F, TTL (Fig 2).

**Results and Discussion**

**Determination of binding activities by fluorescence polarization assay**

The in vitro and in vivo properties of MMAE have previously been described in detail both for the free drug and as an ADC [24]. The augmented activity and properties of the carboxy-terminally charged monomethyl auristatin F (MMAF) derivative have likewise been reported for both cleavable and non-cleavable conjugates [25]. However, direct equilibrium dissociation
constants, $K_D$’s, of auristatins to free tubulin have not been reported. Reliable and facile $K_D$ measurements have proved challenging due to both the complexity of the protein system being investigated and the propensity of the auristatin ligands to promote longitudinal aggregation of the tubulin dimers. We have developed a simple and highly reproducible fluorescence polarization assay to ascertain the binding activity of FITC conjugated analogs of MMAE (FI-MMAE) and MMAF (FI-MMAF) and which can be used to evaluate either the $K_D$ values of FITC conjugates directly or the apparent IC$_{50}$ values of unlabeled chemotypes in competition assays. Fluorescence polarization binding measurements of FI-MMAE and FI-MMAF to free tubulin demonstrate $K_D$ values of 291 and 60 nM (±3 nM), respectively (Fig 1B). These measurements demonstrate nearly a ~5 fold increase in the binding affinity by the replacement of the carboxy-terminal norephedrine moiety of MMAE with the phenylalanine amino acid found in MMAF. These results further suggest that the >100 fold increase in cellular toxicity exhibited by membrane permeable MMAF analogs over MMAE [25] is at least partly a result of enhanced tubulin binding affinity.
The crystal structure of tubulin in complex with MMAAs

To investigate the specific mode of binding as well as differences in activity between MMAE and MAAF, we used a protein complex composed of two αβ-tubulin (T2), the stathmin-like protein RB3, and tubulin tyrosine ligase (TTL), and determined the crystal structures of both the liganded auristatin analogs MMAE (T2R-TTL-MMAE) and MMAF (T2R-TTL-MMAF) at 1.8 and 2.5 Å resolution (Table 1). Furthermore, to compare their binding modes to vinblastine in the same crystal form, we determined the crystal structure of T2R-TTL in complex with vinblastine to 2.2 Å resolution (Table 1). The T2R-TTL-MMAE and T2R-TTL-MMAF structures are
nearly identical (RMSD of 0.24 Å over 440 Cα atoms; β1-tubulin chain), and are highly similar to the drug-free T2R-TTL complex [22] (PDB-ID 4IHJ; 0.26 Å over 440 Cα atoms). The T2R-TTL-vinblastine structure is also very similar and superimposes to the β1-tubulin chain of T2R-TTL-MMAE with an RMSD of 0.50 Å over 375 Cα atoms.

Consistent with other structural reports for peptide based vinca-site binders [18,19], MMAE binds at a distinct and previously suggested peptide site [14] on the β-tubulin subunit at the inter-dimer interface between two longitudinally aligned tubulin molecules (Fig 2A). However, in contrast to vinblastine [15], MMAE also interacts with the exposed β2-tubulin subunit of the second tubulin dimer in the T2R-TTL complex (Fig 2A). This mode of binding agrees with other structural reports for peptide based vinca-site binders and further confirms a distinct and previously suggested peptide site on the β2-tubulin subunit [18,19]. The amino-terminus of MMAE projects into the vinblastine binding site, however, the carboxy-terminal end extends further into the interdimer interface to position the terminal norephedrine group directly above the bound GDP ligand (Fig 2B). As a consequence, and compared to vinblastine, which interacts almost equally across the interface (326 Å2 β1-tubulin, 359 Å2 α2-tubulin), MMAE shares a greater buried surface area with the β1-tubulin subunit (457 Å2) than with the adjacent α2-tubulin subunit (273 Å2). The MMAE binding site is composed of the β1-tubulin T5 loop, the carboxy-terminal end of the H6 helix, the H6-H7 loop, the amino-terminus of the H7 helix and the H1 helix (Fig 2B). The site is completed on the α2-tubulin subunit side by the S9 strand, the H10 helix and the T7 loop. Unlike the binding mode of vinblastine, the MMAE molecule is elongated towards the nucleotide binding site, forming more extensive interactions with the β1-tubulin subunit H6-H7 loop and H7 helix. This binding mode is more similar to phomopsin and soblidotin; however, unlike these agents, the carboxy-terminus of the MMAE molecule interacts with the H1 helix and rests directly on the purine carbonyl oxygen of the GDP ligand [18]. The members of the auristatin class of molecules have been shown to potently inhibit nucleotide exchange on tubulin without displacement of the bound nucleotide [14], and the interactions proximal to the bound GDP ligand confirm a structural basis for this biochemical property.

The detailed MMAE binding mode

The high resolution crystal structure of MMAE elucidates the specific interactions that are essential for both the affinity and potency for this class of molecules [12]. Starting with the amino-terminal end of the MMAE molecule, the nitrogen of the methylated valine amino terminus forms a hydrogen bond to one side chain carboxylate oxygen of Asp179, found on the T5 loop of the β1-tubulin subunit (Fig 2C). It is interesting to note that the geometry of the methylamine group in this position interacts with only one of the δ oxygen atoms of the Asp179 carboxylate. The interaction with the other oxygen atom occurs through a coordinated crystallographic water molecule. The second residue in the MMAE molecule is a natural amino acid valine, and this side chain projects into a hydrophobic pocket on the adjacent α-tubulin subunit. Importantly, both the amide nitrogen and carbonyl moieties of the MMAE backbone here also interact with the α2-tubulin subunit through hydrogen bonds to the Asn329 side chain Oδ1 and Nδ2 atoms, respectively. The same carbonyl additionally co-coordinates a crystallographic water molecule that is shared with the carbonyl of the backbone for Pro222 of the β1-tubulin subunit (Fig 2C).

The side chain of the γ-amino acid Dolaisoleuine occupies a hydrophobic pocket located on the β1-tubulin subunit and the O-methyl group of this residue orients the subsequent carbonyl towards the formation of a hydrogen bond to the amide backbone of the Tyr224 residue on the β1-tubulin subunit (Fig 2D). Likewise, the Dolaproline residue maintains a particular
configuration for the positioning of its carboxy-terminal carbonyl to maintain a hydrogen bond with the amide backbone of Gly225. Also in this region, the tyrosyl ring of Tyr224 is shifted 1 Å away from the GDP as compared to the drug free tubulin structure, likely as a result of auristatin binding. The phenyl group of the carboxy-terminal norephephedrine residue is perfectly oriented to stabilize the bound GDP ligand. The phenyl ring occupies a groove flanked by Tyr224 and Gln15 of the β2-tubulin subunit, and the hydroxyl group forms both a hydrogen bond to the Oe2 of Gln15 and coordinates a water molecule with the Nδ2 of Asn228 (Fig 2D).

Importantly, the Gln15 side chain is rotated from the position found in both the drug free tubulin and the tubulin-vinblastine structures, and this adjustment moves the Oe2 atom ~4Å away from a hydrogen bond to the O6 guanosine carbonyl of the bound GDP. Our crystallographic analysis highlights the importance of the unique Dolaisoleuine and Dolaproine γ-amino acids which maintain a precise distance and angular orientation of each respective carbonyl group to form hydrogen bonds to the backbone amides of β1-tubulin Tyr224 and Gly225 in the T2R-TTL complex. These two hydrogen bonds critically maintain the auristatin association to the β2-tubulin subunit that is otherwise solvent exposed in this region, and serve to position the carboxy-terminus in a location ideal for the inhibition of nucleotide exchange (Fig 2B). This association is further stabilized by the trans-configuration (next paragraph) at the amide bond between the Valine and Dolaisoleuine constituents, which favorably orients the backbone amide and carbonyl of MMAE to form additional hydrogen bonds to both the backbone carbonyl of Pro222 and the Asn329 side chain of the longitudinally aligned α2-tubulin subunit. These observations are in agreement with the SAR-study presented by Pettit and coworkers [12] and with the binding mode that was recently described by Wang and co-workers [26].

The trans-configuration at the Val-Dil amide bond

Interestingly, the reported 3.1 Å crystal structures of dolastatin 10 and amino-terminal auristatin analogs denote a cis-configuration between the Valine and Dil components of the bound ligand at this location [19]. Moreover, in these structures the cis-configuration is only seen by ligands bound at the β1/α2 tubulin interface, whereas those bound to the free β2-tubulin subunit display the lower energy trans-configuration. These observations, along with NMR solution data supporting a trans-configuration for free auristatin analogs, has led to the proposal that auristatins and related molecules maintain a trans-configuration during initial β1-tubulin subunit binding and reconfigure to a cis-amide upon subsequent α2–tubulin subunit addition. Although not discussed by Maderna and co-workers [19], it is also possible that trans-/cis-switching occurred under soaking conditions and that the cis-conformer of the peptide was crystallized. In contrast to these previous observations, both the T2R-TTL-MMAE and T2R-TTL-MMAF structures unambiguously display a trans-configuration for the amide bond between the Valine and Dil constituents of the bound ligands at the β1/α2 tubulin interface (Fig 2B and 2C).

The detailed MMAF binding mode

Compared to MMAE, the specific interactions for the MMAF ligand are maintained at all positions with the exception of the carboxy-terminal phenylalanine group (Fig 3A). Although the phenyl group similarly occupies the groove between β1-tubulin Tyr224 and Gln15, there are no specific interactions with either Gln15 or a coordinated water molecule with Asn228 due to the lack of a hydroxyl in this position (Fig 3A). Despite the absence of a specific interaction, the Gln15 is still repositioned away from the bound GDP, suggesting that this change in the β1-tubulin subunit upon ligand binding is the result of steric interactions at the apical region of the nucleotide binding site. The carboxylic acid of the phenylalanine tilts towards the positively
charged pocket defined by \( \beta_1 \)-tubulin His229, Lys19 and Arg278 (Fig 3B) and in this orientation a carboxylate oxygen coordinates a crystallographic water molecule which is shared via hydrogen bond to the guanidinium group of Arg278.

Crystal binding structure of \( T_2R-TTL \) in complex with vinblastine

The binding mode of vinblastine has been described in terms of tubulin secondary-structure elements due to the moderate resolution [15,16]. The high resolution crystal structure of the \( T_2R-TTL \)-vinblastine complex presented in this study now allows to describe the detailed interactions in the binding site and to compare them to the binding of MMAE and MMAF. The vinblastine binding site at the interdimer interface is shaped by the \( \beta_1 \)-tubulin subunit T5 loop, the carboxy-terminal end of helix H6, the H6-H7 loop and the amino-terminus of the helix H7. The T7 loop, the S9 strand and the helix H10 of \( \alpha_2 \)-tubulin shape the remaining part of the binding site (Fig 4). Similar to MMAE (Fig 2C) vinblastine forms two hydrogen bonds to Asn329, one direct and one water-mediated hydrogen bond to the backbone carbonyl of Pro222, thereby establishing a crosstalk to Asp226 and Arg278. Additional hydrogen bonds are formed by the tertiary amine of the catharanthine moiety to a water molecule connecting the T5 loop backbone carbonyl of Val177, the carboxylate of Asp179 and the hydroxyl group of Tyr224 that contacts the ribose 2'-hydroxyl group of the bound nucleotide (Fig 4).

Extended M-loop stabilization by MMAs and vinblastine

The comparison of the three structures additionally highlights the key Arg278 residue on the \( \beta_1 \)-tubulin subunit that is in contact with MMAF via an ordered water molecule and which likely explains the increased affinity observed for MMAF. This interaction is of special interest.
because Arg278 is located on the highly flexible β-tubulin M-loop, a secondary structure element that becomes helically structured upon tubulin assembly into microtubules, and which partially defines the taxane site to which microtubule-stabilizing agents bind [27]. High resolution crystal structures of tubulin liganded with taxane-site binding agents show a well ordered helical M-loop region [21]. To date, crystal structures solved in the absence of such stabilizing agents exhibit an M-loop that is either disordered (T2R-TTL-apo, PDB ID 4IHJ, Fig 5C) or it preferentially adopts a poorly defined, extended conformation without clear secondary structure [15,18,22–34]. In this extended M-loop conformation the Arg278 side chain is favorably oriented to interact with Asp226 located at the amino-terminus of helix H7. This same orientation is observed in the T2R-TTL-MMAE, the T2R-TTL-MMAF and the T2R-TTL-vinblastine structures (Fig 5A and 5B), which either stabilize the ordered solvent surrounding the Arg278/Asp226 interaction through a distinct hydrogen bonding network (Fig 3A), or through the stabilization of the β1-tubulin H6/H7 loop (Fig 4). In the case of MMAF, the stabilization effect is even strengthened by the presence of a terminal carboxylate in proximity of the guanidinium group of Arg278. In the MMAE bound structure, the carboxylate is not present; however, an ordered crystallographic water molecule forms a bidentate interaction with Arg278 and is within hydrogen bonding distance to both Thr223 and the carbonyl of Dolaprine (Fig 3A). This extended hydrogen bond network to Arg278 may well serve to maintain the β-tubulin M-loop in an extended conformation that would be incompatible with the helical one seen in microtubules [35,36]. This conformation is distinct from the compatible conformation observed in the crystal structures of tubulin liganded by taxane site microtubule stabilizing agents (Fig 5D) and could therefore augment the destabilizing potential of auristatins.

Fig 4. The detailed tubulin-vinblastine interactions at the vinca site. Vinblastine is in violet/purple stick representation. β1- and α2-tubulin are displayed as light and dark grey ribbons, respectively. Key residues forming the interaction with the ligand are in stick representation and are labeled. Hydrogen bonds are highlighted as dashed black lines, water molecules as red spheres.

doi:10.1371/journal.pone.0160890.g004
Conclusions

Our high-resolution crystallographic comparison of the binding modalities of MMAE and MMAF lends valuable insight into the specific interactions that give rise to the nano- and picomolar potency of these antimitotic agents in cellular assays. The analysis provides a structural explanation why the presence of a negatively charged phenylalanine group at the carboxy-terminus of MMAF increases the binding to free tubulin over the uncharged norephedrine of MMAE, and likely explains the >100-fold increase in cytotoxicity exhibited by MMAF analogs [25]. We show that detailed structural interactions that extend the vinca domain to the peptide site are not only functionally distinct by inhibiting nucleotide exchange, but also indicate how peptide site antimitotics attain increased potency over the vinca alkaloids.
While preparing this manuscript, an article by Wang Y. and coworkers was published, which describes the crystal structures of both MMAE and vinblastine at 2.5 Å resolution [26]. The article by Wang and coworkers describes the binding modes of the ligands and discusses the pharmacophoric aspects of ligand binding to the vinca-site, which is distinct from the focus of the work described in this manuscript.

The established mechanisms of microtubule depolymerization by the auristatins include curvature induction, longitudinal polymerization and inhibition of nucleotide exchange. Our analysis of high resolution crystallographic structures now suggests the possibility of a fourth component, that of extended M-loop stabilization, to this highly potent class of antimitotics. Although additional research will be necessary to further explore this hypothesis, these structural findings represent a significant step towards our understanding of the cytotoxic potency of auristatins and other peptide-site binding agents at the atomic level.

Acknowledgments

We thank A. Pauluhn, V. Olieric and M. Wang for excellent technical assistance with the collection of X-ray data at beamlines X10SA and X06SA of the Swiss Light Source (Paul Scherrer Institut, Villigen, Switzerland) and Jay Nix for support at beamline 4.2.2 at the Advanced Light Source (Lawrence Berkeley Labs, Berkeley, USA).

Author Contributions

Conceptualization: ABW MOS DS AEP.

Data curation: ABW AEP.

Formal analysis: ABW MOS DS AEP.

Funding acquisition: MOS DS AEP.

Investigation: ABW MOS DS AEP.

Methodology: ABW KB SD AEP.

Project administration: ABW MOS DS AEP.

Supervision: ABW MOS DS AEP.

Validation: ABW AEP.

Visualization: ABW AEP.

Writing - original draft: ABW KB SD MOS DS AEP.

Writing - review & editing: ABW KB SD MOS DS AEP.

References

1. Hyman AA, Salser S, Drechsel DN, Unwin N, Mitchison TJ (1992) Role of GTP hydrolysis in microtubule dynamics: information from a slowly hydrolyzable analogue, GMPCPP. Mol Biol Cell 3: 1155–1167. PMID: 1421572

2. Mitchison T, Kirschner M (1984) Dynamic instability of microtubule growth. Nature 312: 237–242. PMID: 6504138

3. Purich DL, Kristofferson D (1984) Microtubule assembly: a review of progress, principles, and perspectives. Adv Protein Chem 36: 133–212. PMID: 6382962

4. Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 13: 83–117. PMID: 9442869
5. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253–265. PMID: 15057285
6. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T (2011) Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8: 244–250. doi: 10.1038/nrclinonc.2010.228 PMID: 21283127
7. Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. (1963) The Vinca Alkaloids: A New Class of Oncolytic Agents. Cancer Res 23: 1390–1427. PMID: 14070392
8. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55: 31–51. PMID: 1287674
9. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. (2003) cAC10-vcMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 1458–1465. PMID: 12714494
10. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–9290. doi: 10.1158/0008-5472.CAN-08-1776 PMID: 19010901
11. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, et al. (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18: 5845–5849. doi: 10.1158/1078-0432.CCR-12-1803 PMID: 22962441
12. Pettit GR (1997) The dolastatins. Fortschr Chem Org Naturst 70: 1–79. PMID: 9088158
13. Pettit GR, Srirangam JK, Barkocy J, Williams MD, Boyd MR, Hamel E, et al. (1998) Antineoplastic agents 365. Dolastatin 10 SAR probes. Anticancer Drug Des 13: 243–277. PMID: 9627667
14. Bai RL, Pettit GR, Hamel E (1990) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 17141–17149. PMID: 2211617
15. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, et al. (2005) Structural basis for the regulation of tubulin by vinblasticine. Nature 435: 519–522. PMID: 15917812
16. Ranairovson FM, Gigant B, Bennitt S, Joulie M, Knossow M (2012) Structural plasticity of tubulin assembled by vinca-domain ligands. Acta Crystallogr D Biol Crystallogr 68: 927–934. doi: 10.1107/S000170921105269X
17. Bai R, Pettit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941–1949. PMID: 2353935
18. Cormier A, Marchand M, Ravelli RB, Knossow M, Gigant B (2008) Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep 9: 1101–1106. doi: 10.1038/embor.2008.171 PMID: 18787557
19. Maderna A, Doroski M, Subramanyam C, Porte A, Leverett CA, Vetelino BC, et al. (2014) Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem 57: 10527–10543. doi: 10.1021/jm501649k PMID: 25431858
20. Andreu JM (2007) Large scale purification of brain tubulin with the modified Weisenberg procedure. Methods Mol Med 137: 17–28. PMID: 18085219
21. Prota AE, Bargsten K, Zurwerra D, Field JJ, Diaz JF, Altmann KH, et al. (2013) Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science 339: 587–590. doi: 10.1126/science.1230582 PMID: 23287720
22. Prota AE, Magiera MM, Kuijpers M, Bargsten K, Frey D, Wieser M, et al. (2013) Structural basis of tubulin tyrosination by tubulin tyrosine ligase. J Cell Biol 200: 259–270. doi: 10.1083/jcb.201211017 PMID: 23358242
23. Curmi PA, Maucuer A, Asselin S, Lecourtouir L, Chaffotte A, Schmitter JM, et al. (1994) Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63). Biochem J 300 (Pt 2): 331–338. PMID: 8002936
24. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778–784. doi: 10.1038/nbt890. PMID: 12778055
25. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17: 114–124. PMID: 16417259
26. Wang Y, Benz FW, Wu Y, Wang G, Chen Y, Chen X, et al. (2016) Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules. Mol Pharmacol 89: 239–242. doi: 10.1124/mol.115.100149 PMID: 26660762
27. Snyder JP, Nettles JH, Comrett B, Downing KH, Nogales E (2001) The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 98: 5312–5316. PMID: 11309480

28. Dorleans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, Knossow M (2009) Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci U S A 106: 13775–13779. doi:10.1073/pnas.0904223106 PMID: 19666559

29. Nawrotek A, Knossow M, Gigant B (2011) The determinants that govern microtubule assembly from the atomic structure of GTP-tubulin. J Mol Biol 412: 35–42. doi: 10.1016/j.jmb.2011.07.029 PMID: 21787788

30. Pecqueur L, Duellberg C, Dreier B, Jiang Q, Wang C, Pluckthun A, et al. (2012) A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end. Proc Natl Acad Sci U S A 109: 12011–12016. doi: 10.1073/pnas.1204129109 PMID: 22778434

31. Prota AE, Bargsten K, Diaz JF, Marsh M, Cuevas C, Liniger M, et al. (2014) A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A 111: 13817–13821. doi: 10.1073/pnas.1408124111 PMID: 25114240

32. Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, Miller JH, et al. (2014) Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl 53: 1621–1625. doi: 10.1002/anie.201307749 PMID: 24470331

33. Prota AE, Danel F, Bachmann F, Bargsten K, Buey RM, Pohlmann J, et al. (2014) The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol 426: 1848–1860. doi: 10.1016/j.jmb.2014.02.005 PMID: 24530796

34. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198–202. PMID: 15014504

35. Alushin GM, Lander GC, Kellogg EH, Zhang R, Baker D, Nogales E (2014) High-resolution microtubule structures reveal the structural transitions in alphabeta-tubulin upon GTP hydrolysis. Cell 157: 1117–1129. doi: 10.1016/j.cell.2014.03.053 PMID: 24855948

36. Zhang R, Alushin GM, Brown A, Nogales E (2015) Mechanistic Origin of Microtubule Dynamic Instability and Its Modulation by EB Proteins. Cell 162: 849–859. doi: 10.1016/j.cell.2015.07.012 PMID: 26234155